Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

This phase I trial studies the side effects and how well IL13Ralpha2-CAR T cells work when given alone or together with nivolumab and ipilimumab in treating patients with glioblastoma that has come back (recurrent) or does not respond to treatment (refractory). Biological therapies, such as IL13Ralpha2-CAR T cells, use substances …

cytotoxic chemotherapy
hepatitis
recurrent disease
ipilimumab
dexamethasone
  • 0 views
  • 11 Nov, 2021
  • 1 location
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. …

neutrophil count
temozolomide
recurrent disease
immunohistochemistry
serum pregnancy test
  • 0 views
  • 24 Jan, 2021
  • 1 location
B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma …

neutrophil count
temozolomide
recurrent disease
immunohistochemistry
serum pregnancy test
  • 0 views
  • 25 Jan, 2021
  • 3 locations
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).

  • 0 views
  • 20 Jun, 2022
  • 112 locations
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In this study …

temozolomide
MRI
tumor cells
EGFR
tumor treating fields therapy
  • 0 views
  • 14 Mar, 2022
  • 1 location
VB-111 in Surgically Accessible Recurrent/Progressive GBM

This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

renal function test
vascular endothelial growth factor
dexamethasone
tumor progression
investigational agent
  • 0 views
  • 15 Jun, 2022
  • 1 location
ASP8374 + Cemiplimab in Recurrent Glioma

This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given …

malignant glioma
recurrent malignant glioma
  • 0 views
  • 04 Jul, 2022
  • 2 locations
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)

the association of hypofractionated stereotactic radiation therapy (hFSRT) and the anti-PD-L1 Durvalumab immunotherapy in patients with recurrent glioblastoma. A maximum number of 12 patients will be

malignant glioma
karnofsky performance status
contrast-enhanced magnetic resonance imaging
vascular endothelial growth factor
recurrent glioblastoma
  • 0 views
  • 05 Apr, 2022
  • 8 locations
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted

brain tumor
renal function test
blood transfusion
recurrent disease
platelet count
  • 40 views
  • 24 Apr, 2022
  • 17 locations
  • 0 views
  • 01 Jul, 2022
  • 47 locations